About
Treatments for neuronal Excitability Disorders
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
137
By Phase
PHASE2: 1EARLY_PHASE1: 1PHASE1: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07096843Lead Sponsor
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
PHASE2Recruiting
45 participants
Started: Aug 25, 2025 · Completed: Oct 31, 2027
NCT07090655Lead Sponsor
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
EARLY_PHASE1Recruiting
38 participants
Started: Aug 11, 2025 · Completed: Jun 30, 2026
NCT07011043Lead Sponsor
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
PHASE1Recruiting
30 participants
Started: Jul 10, 2025 · Completed: Apr 30, 2027
NCT07043946Lead Sponsor
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
PHASE1/PHASE2Recruiting
24 participants
Started: Jun 30, 2025 · Completed: Aug 31, 2028
Locations (1)
Headquarters
Wellesley Hills, MA, United States
Map
Loading map...